MA50858A - Procédés, compositions et composants pour l'édition crispr-cas9 de tgfbr2 dans des cellules t pour l'immunothérapie - Google Patents

Procédés, compositions et composants pour l'édition crispr-cas9 de tgfbr2 dans des cellules t pour l'immunothérapie

Info

Publication number
MA50858A
MA50858A MA050858A MA50858A MA50858A MA 50858 A MA50858 A MA 50858A MA 050858 A MA050858 A MA 050858A MA 50858 A MA50858 A MA 50858A MA 50858 A MA50858 A MA 50858A
Authority
MA
Morocco
Prior art keywords
tgfbr2
cas9
crispr
immunotherapy
edition
Prior art date
Application number
MA050858A
Other languages
English (en)
Inventor
Stephen Michael Burleigh
Melissa Chin
Fred Harbinski
Christopher Heath Nye
Blythe D Sather
Queenie Vong
Gordon Grant Welstead
Chris Wilson
Original Assignee
Editas Medicine Inc
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Editas Medicine Inc, Juno Therapeutics Inc filed Critical Editas Medicine Inc
Publication of MA50858A publication Critical patent/MA50858A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Enzymes And Modification Thereof (AREA)
MA050858A 2017-11-01 2018-11-01 Procédés, compositions et composants pour l'édition crispr-cas9 de tgfbr2 dans des cellules t pour l'immunothérapie MA50858A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762580320P 2017-11-01 2017-11-01

Publications (1)

Publication Number Publication Date
MA50858A true MA50858A (fr) 2020-09-09

Family

ID=64453598

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050858A MA50858A (fr) 2017-11-01 2018-11-01 Procédés, compositions et composants pour l'édition crispr-cas9 de tgfbr2 dans des cellules t pour l'immunothérapie

Country Status (13)

Country Link
US (1) US12698489B2 (fr)
EP (1) EP3704251A2 (fr)
JP (3) JP7785452B2 (fr)
KR (1) KR102954207B1 (fr)
CN (1) CN111527209B (fr)
AU (2) AU2018358250B2 (fr)
BR (1) BR112020008478A2 (fr)
CA (1) CA3081456A1 (fr)
IL (1) IL274299B2 (fr)
MA (1) MA50858A (fr)
MX (2) MX2020004608A (fr)
SG (1) SG11202003862PA (fr)
WO (1) WO2019089884A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019165121A1 (fr) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Procédés d'activation et d'expansion de cellules tueuses naturelles et utilisations de celles-ci
CN110904045A (zh) * 2018-09-17 2020-03-24 中国科学院动物研究所 经修饰的t细胞、其制备方法及用途
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
CA3136737A1 (fr) * 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cellules exprimant un recepteur recombinant a base d'un locus modifie du tgfbr2, et polynucleotides et methodes associes
EP4768574A2 (fr) 2019-05-29 2026-07-01 Monsanto Technology LLC Procédés et compositions pour générer des allèles dominants à l'aide d'édition de génome
US12024711B2 (en) 2019-05-29 2024-07-02 Monsanto Technology Llc Methods and compositions for generating dominant short stature alleles using genome editing
CN114174325A (zh) * 2019-06-04 2022-03-11 恩卡尔塔公司 用于免疫疗法的工程化自然杀伤细胞和工程化t细胞的组合
EP3999527A4 (fr) * 2019-07-18 2024-04-17 Memorial Sloan Kettering Cancer Center Procédés et compositions pour cibler la signalisation du tgf-beta dans des lymphocytes t auxiliaires cd4+ pour immunothérapie anticancéreuse
EP4061927A4 (fr) * 2019-11-20 2024-11-13 Cartherics Pty. Ltd. Procédé de fourniture de cellules immunitaires à fonction améliorée
EP4076476A4 (fr) * 2019-12-17 2023-11-22 The General Hospital Corporation Cellules immunitaires modifiées à toxicité réduite et leurs utilisations
CN114929250A (zh) * 2019-12-18 2022-08-19 爱迪塔斯医药公司 用于疗法的经工程化的细胞
US20230096378A1 (en) 2020-03-12 2023-03-30 Institute For Basic Science Composition for inducing apoptosis of cells having genomic sequence variation and method for inducing apoptosis of cells by using composition
CN114164231B (zh) * 2020-09-10 2024-05-17 上海邦耀生物科技有限公司 对细胞中的靶位点进行基因编辑的方法
KR20230074515A (ko) * 2020-09-23 2023-05-30 크리스퍼 테라퓨틱스 아게 개선된 기능성 및 지속성을 갖는 붕괴된 레그나제-1 및/또는 tgfbrii를 지니는 유전자 조작된 t 세포
AU2022216614B2 (en) 2021-02-05 2026-03-05 Christiana Care Gene Editing Institute, Inc. Methods of and compositions for reducing gene expression and/or activity
JP2024517641A (ja) * 2021-04-20 2024-04-23 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 免疫細胞の遺伝子改変および治療的使用のための方法および組成物
WO2023081900A1 (fr) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Lymphocytes t modifiés exprimant un récepteur recombiné de lymphocytes t (tcr) et systèmes et procédés apparentés
EP4469577A4 (fr) * 2022-01-26 2026-04-15 Orthobio Therapeutics Inc Édition de gène pour améliorer la fonction articulaire
US20230331841A1 (en) * 2022-03-23 2023-10-19 Crispr Therapeutics Ag Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption
WO2024058589A1 (fr) * 2022-09-16 2024-03-21 한국과학기술연구원 Cellule de récepteur antigénique chimérique préparée à l'aide d'une technique de knock-in par ciseaux génétiques et son utilisation
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向ｐｓｍａ及ｃａ９之系統
CN116515766A (zh) * 2023-06-30 2023-08-01 上海贝斯昂科生物科技有限公司 一种自然杀伤细胞、其制备方法及用途
WO2025038637A1 (fr) * 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Compositions et procédés de modification génétique du récepteur bêta du facteur de croissance transformant de type 2 (tgfβr2)
WO2025038648A1 (fr) * 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Compositions et méthodes de modification génétique du récepteur bêta du facteur de croissance transformant de type 2 (tgfβr2)
WO2025137646A1 (fr) 2023-12-22 2025-06-26 Recode Therapeutics, Inc. Méthodes d'édition de gènes et compositions pour le traitement de la fibrose kystique
WO2025165915A1 (fr) * 2024-01-31 2025-08-07 Adicet Therapeutics, Inc. Compositions et procédés d'amélioration de thérapies par lymphocytes t modifiés
US20250345431A1 (en) 2024-05-10 2025-11-13 Juno Therapeutics, Inc. Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
WO2026067458A1 (fr) * 2024-09-24 2026-04-02 Geneditbio Limited Méthodes et compositions pour l'édition génique et la thérapie du gène tgfbi utilisant un système crispr et un véhicule d'administration de protéines modifié
WO2026123001A2 (fr) 2024-12-06 2026-06-11 Umoja Biopharma, Inc. Thérapie par cellules modifiées à loci spécifiques de lignée et procédés de production et d'utilisation associés
WO2026136848A2 (fr) 2024-12-20 2026-06-25 Juno Therapeutics, Inc. Récepteurs car ciblant cd70, cellules modifiées les comprenant et procédés associés

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
IN165717B (fr) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (fr) 1994-10-26 1996-05-09 Procept, Inc. Recepteurs de lymphocites t monocatenaires solubles
WO1996018105A1 (fr) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Recepteur de lymphocyte t monocatenaire
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
CA2305630C (fr) 1997-10-02 2012-11-06 Sunol Molecular Corporation Proteines solubles du recepteur des lymphocytes t a chaine unique
NZ507886A (en) 1998-05-19 2003-05-30 Avidex Ltd Multivalent T cell receptor complexes
WO2000014257A1 (fr) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Recepteurs de fusion specifiques a l'antigene prostatique specifique membranaire et ses utilisations
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
CA2410510A1 (fr) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Cellules presentatrices d'antigene artificiel et leurs methodes d'utilisation
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
EP2305813A3 (fr) * 2002-11-14 2012-03-28 Dharmacon, Inc. SIRNA fonctionnel et hyperfonctionnel
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
EP1791865B1 (fr) 2004-06-29 2010-07-28 Immunocore Ltd. Cellules exprimant une cellule t recepteur modifiee
EP1809669A2 (fr) 2004-10-01 2007-07-25 Avidex Ltd Recepteurs de lymphocytes t a liaison intercatenaire disulfure exogene reliee a des agents therapeutiques
WO2008109546A2 (fr) 2007-03-02 2008-09-12 Mdrna, Inc. Composés d'acide nucléique pour inhiber l'expression du gène tgfbr et utilisations de ceux-ci
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
WO2011044186A1 (fr) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Récepteurs de lymphocytes t à chaîne unique humains
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012129514A1 (fr) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Méthodes et compositions pour une immunothérapie cellulaire
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
WO2013071154A1 (fr) 2011-11-11 2013-05-16 Fred Hutchinson Cancer Research Center Immunothérapie par des lymphocytes t ciblant la cycline a1 pour le traitement du cancer
EP2814846B1 (fr) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Récepteurs d'antigène chimères bispécifiques et utilisations thérapeutiques de ceux-ci
WO2013126726A1 (fr) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
WO2014055815A1 (fr) 2012-10-05 2014-04-10 Cincinnati Children's Hospital Medical Center Culture de sébocytes et leurs procédé d'utilisation
JP5372297B1 (ja) 2012-12-20 2013-12-18 三菱電機株式会社 車載装置及びプログラム
CN105408483A (zh) * 2013-03-15 2016-03-16 通用医疗公司 遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向
WO2014204723A1 (fr) 2013-06-17 2014-12-24 The Broad Institute Inc. Modèles oncogènes basés sur la distribution et l'utilisation de systèmes crispr-cas, vecteurs et compositions
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
WO2015048577A2 (fr) 2013-09-27 2015-04-02 Editas Medicine, Inc. Compositions et méthodes relatives aux répétitions palindromiques groupées, courtes et régulièrement espacées
CN111218447B (zh) * 2013-11-07 2024-10-11 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
US9938521B2 (en) 2014-03-10 2018-04-10 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)
SG11201608701QA (en) * 2014-04-18 2016-11-29 Editas Medicine Inc Crispr-cas-related methods, compositions and components for cancer immunotherapy
WO2016073990A2 (fr) 2014-11-07 2016-05-12 Editas Medicine, Inc. Procédés pour améliorer l'édition génomique médiée par crispr/cas
EP3020813A1 (fr) * 2014-11-16 2016-05-18 Neurovision Pharma GmbH Oligonculéotides antisens en tant qu'inhibiteurs de la signalisation de TGF-R
EP4339287A3 (fr) 2015-07-31 2024-05-22 Regents Of The University Of Minnesota Cellules modifiées et procédés de thérapie
SG10201913151TA (en) * 2015-09-09 2020-03-30 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Genetic engineering of macrophages for immunotherapy

Also Published As

Publication number Publication date
JP7785452B2 (ja) 2025-12-15
WO2019089884A3 (fr) 2019-06-13
EP3704251A2 (fr) 2020-09-09
CN111527209B (zh) 2024-11-12
IL274299A (en) 2020-06-30
IL274299B1 (en) 2026-01-01
KR102954207B1 (ko) 2026-04-16
US12698489B2 (en) 2026-08-04
JP2025156493A (ja) 2025-10-14
CN111527209A (zh) 2020-08-11
SG11202003862PA (en) 2020-05-28
RU2020117752A (ru) 2021-12-01
US20230061455A1 (en) 2023-03-02
KR20200075000A (ko) 2020-06-25
JP2023179469A (ja) 2023-12-19
AU2025223904A1 (en) 2025-09-18
MX2020004608A (es) 2020-10-05
AU2018358250A1 (en) 2020-05-14
MX2025010535A (es) 2025-10-01
CA3081456A1 (fr) 2019-05-09
WO2019089884A2 (fr) 2019-05-09
AU2018358250B2 (en) 2025-06-05
BR112020008478A2 (pt) 2020-10-20
IL274299B2 (en) 2026-05-01
JP2021502113A (ja) 2021-01-28

Similar Documents

Publication Publication Date Title
EP3370741A4 (fr) Procédés et compositions pour l'édition de gènes dans des cellules souches hématopoïétiques
EP3793579A4 (fr) Procédés et compositions pour générer des cellules de lignée endodermique et des cellules bêta et utilisations associées
MA47331A (fr) Compositions et procédés pour la déplétion des cellules cd137+
EP3472178A4 (fr) Compositions et procédés pour la déplétion des cellules cd117+
FR23C1015I1 (fr) Procédés de sélection d'une lignée de lymphocytes t et donneur de lignée de lymphocytes t pour thérapie cellulaire adoptive
IL274299A (en) Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
EP3371301A4 (fr) Procédés et compositions pour induire la différenciation de cellules hématopoïétiques
EP3503901A4 (fr) Procédés et compositions pour cellules de moelle épinière
MA49981A (fr) Procédés et compositions de préparation de cellules génétiquement modifiées
EP3490366A4 (fr) Procédés et compositions pour l'expression de gènes dans des plantes
EP3429603A4 (fr) Procédés et compositions concernant l'expansion de cellules souches hématopoïétiques
EP3405568A4 (fr) Compositions et procédés de modulation des cellules immunitaires en immunothérapies adoptives
EP3886877A4 (fr) Procédés d'expansion simultanée de multiples types de cellules immunitaires, compositions associées et utilisations de celles-ci dans l'immunothérapie contre le cancer
EP3717022A4 (fr) Compositions et procédés pour la déplétion des cellules cd5+
EP3307284A4 (fr) Compositions et procédés pour l'enrichissement de cellules
MA43943A (fr) Compositions et procédés pour traiter des patients avec des cellules mutantes rtk
MA49979A (fr) Procédés de production de compositions de cellules génétiquement modifiées et compositions associées
EP3635100A4 (fr) Compositions et procédés pour exprimer l'otoferline
MA53445A (fr) Procédés et compositions pour la modification de plantes
EP3645020A4 (fr) Compositions et procédés pour la thérapie cellulaire adoptive
EP3534911A4 (fr) Procédés et compositions pour la reprogrammation cellulaire
EP3645013A4 (fr) Compositions et procédés pour inhiber l'expression de hmgb1
EP3429609A4 (fr) Compositions et procédés pour le traitement de déficits en collagène de type vii
EP3446123A4 (fr) Procédés et compositions pour pronostiquer une naissance prématurée
IL278201A (en) Methods and preparations for depleting cytotoxic T cells